Suchergebnisse - "Cariou, Bertrand"

PubPharm (5)

1

No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies

enthalten in: European heart journal | 2016

von Colhoun, H. | Ginsberg, H. | Robinson, J. | +8

CommentIn: Nat Rev Cardiol. 2016 Oct;13(10):568-9. - PMID 27510548

2

No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies

enthalten in: European heart journal | 2016

von Colhoun, H. | Ginsberg, H. | Robinson, J. | +8

3

No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies

enthalten in: European heart journal | 2016

von Colhoun, H. | Ginsberg, H. | Robinson, J. | +8

4

Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins : the ODYSSEY COMBO II randomized controlled trial

enthalten in: European heart journal | 2015

von Cannon, C. | Cariou, B. | Blom, D. | +106

CommentIn: Eur Heart J. 2015 May 14;36(19):1146-8. - PMID 25827601

5

Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial

enthalten in: European heart journal | 2015

von Cannon, C. | Cariou, B. | Blom, D. | +5

1
[1]